Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;32(2):82-4.

Clinical features of Pompe disease

Affiliations

Clinical features of Pompe disease

Fiore Manganelli et al. Acta Myol. 2013 Oct.

Abstract

Glycogen storage disease type II - also called Pompe disease or acid maltase deficiency - is an autosomal recessive metabolic disorder, caused by an accumulation of glycogen in the lysosome due to deficiency of the lysosomal acid alpha-glucosidase enzyme. Pompe disease is transmitted as an autosomal recessive trait and is caused by mutations in the gene encoding the acid α-glucosidase (GAA), located on chromosome 17q25.2-q25.3. The different disease phenotypes are related to the levels of residual GAA activity in muscles. The clinical spectrum ranging from the classical form with early onset and severe phenotype to not-classical form with later onset and milder phenotype is described.

Keywords: GAA activity; Glycogen storage disease type II; Pompe disease.

PubMed Disclaimer

References

    1. Ploeg AT, Reuser AJ. Pompe's disease. Lancet. 2008;372:1342–1353. - PubMed
    1. Raben N, Roberts A, Plotz PH. Role of autophagy in the pathogenesis of Pompe disease. Acta Myol. 2007;26:45–48. - PMC - PubMed
    1. Hagemans ML, Winkel LP, Doorn PA, et al. Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients. Brain. 2005;128:671–677. - PubMed
    1. Beek NA, Vries JM, Hagemans ML, et al. Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis. 2012;7:88–88. - PMC - PubMed
    1. Müller-Felber W, Horvath R, Gempel K, et al. Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord. 2009;19:113–117. - PubMed

MeSH terms

LinkOut - more resources